Gufic Biosciences (BOM:509079) Cyclically Adjusted Revenue per Share: ₹73.47 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:509079 Gufic Biosciences Ltd BOM:509079
75 GF Score
Price ₹393.65
GF Value ₹411.59
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gufic Biosciences Cyclically Adjusted Revenue per Share?

Gufic Biosciences BOM:509079 -0.78% 75 Cyclically Adjusted Revenue per Share is ₹73.47 as of Mar. 2026. GuruFocus rates BOM:509079 with a GF Score™ of 75/100 and a GF Value™ of ₹411.59 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Gufic Biosciences's adjusted revenue per share for the three months ended in Mar. 2026 was ₹25.071. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹73.47 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Gufic Biosciences's average Cyclically Adjusted Revenue Growth Rate was 12.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 13.00% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 14.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Gufic Biosciences was 16.70% per year. The lowest was 13.00% per year. And the median was 14.60% per year.

As of today (2026-08-06), Gufic Biosciences's current stock price is ₹393.65. Gufic Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was ₹73.47. Gufic Biosciences's Cyclically Adjusted PS Ratio of today is 5.36.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gufic Biosciences was 7.78. The lowest was 2.50. And the median was 5.03.


Gufic Biosciences  (BOM:509079) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Gufic Biosciences's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=393.65/73.47
=5.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Gufic Biosciences was 7.78. The lowest was 2.50. And the median was 5.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Gufic Biosciences Cyclically Adjusted Revenue per Share Related Terms


Gufic Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Gufic Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gufic Biosciences Cyclically Adjusted Revenue per Share Chart

Gufic Biosciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 43.36 50.86 58.35 65.20 73.47

Gufic Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 65.20 67.58 69.98 71.58 73.47

BOM:509079 vs ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Gufic Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gufic Biosciences Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gufic Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Gufic Biosciences's Cyclically Adjusted PS Ratio falls into.


BOM:509079
75GF Score
Gufic Biosciences Ltd BOM:509079
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gufic Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gufic Biosciences's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=25.071/164.2724*164.2724
=25.071

Current CPI (Mar. 2026) = 164.2724.

Gufic Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 7.097 105.961 11.003
201609 8.229 105.961 12.757
201612 8.294 105.196 12.952
201703 7.763 105.196 12.123
201706 7.829 107.109 12.007
201709 9.614 109.021 14.486
201712 11.535 109.404 17.320
201803 10.031 109.786 15.009
201806 11.721 111.317 17.297
201809 11.801 115.142 16.836
201812 11.329 115.142 16.163
201903 10.813 118.202 15.027
201906 11.937 120.880 16.222
201909 10.994 123.175 14.662
201912 12.532 126.235 16.308
202003 13.192 124.705 17.378
202006 6.363 127.000 8.230
202009 13.264 130.118 16.746
202012 17.232 130.889 21.627
202103 13.672 131.771 17.044
202106 25.874 134.084 31.699
202109 20.049 135.847 24.244
202112 17.753 138.161 21.108
202203 9.893 138.822 11.707
202206 17.037 142.347 19.661
202209 18.079 144.661 20.530
202212 18.327 145.763 20.654
202303 16.760 146.865 18.747
202306 20.142 150.280 22.017
202309 22.127 151.492 23.994
202312 20.217 152.924 21.717
202403 15.744 153.035 16.900
202406 20.227 155.789 21.328
202409 20.354 157.882 21.178
202412 20.774 158.323 21.555
202503 20.450 157.552 21.322
202506 22.252 159.755 22.881
202509 23.672 162.289 23.961
202512 23.097 163.281 23.237
202603 25.071 164.272 25.071

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹73.47 mean?
Gufic Biosciences (BOM:509079) has a Cyclically Adjusted Revenue per Share of ₹73.47 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Gufic Biosciences and its competitors.
Is Gufic Biosciences' Cyclically Adjusted Revenue per Share too high?
Gufic Biosciences' current Cyclically Adjusted Revenue per Share is ₹73.47. Overall, Gufic Biosciences has a GF Score™ of 75/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gufic Biosciences' Cyclically Adjusted Revenue per Share compare to ZTS?
Gufic Biosciences' Cyclically Adjusted Revenue per Share of ₹73.47 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Gufic Biosciences and its competitors. Gufic Biosciences's current Cyclically Adjusted Revenue per Share is ₹73.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gufic Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Gufic Biosciences (BOM:509079) is currently considered Fairly Valued. The stock's GF Value™ is ₹411.59, compared to a current price of ₹393.65 — trading 4.4% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹73.47. Gufic Biosciences' overall GF Score™ is 75/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Gufic Biosciences (BOM:509079), the current Cyclically Adjusted Revenue per Share is ₹73.47 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gufic Biosciences (BOM:509079) Overvalued in 2026?

Based on GuruFocus' analysis, Gufic Biosciences stock appears to be undervalued. The current stock price of ₹393.65 is trading 4.4% below its estimated GF Value™ of ₹411.59. GuruFocus considers Gufic Biosciences to be Fairly Valued.

Key valuation signals for BOM:509079:

  • Cyclically Adjusted Revenue per Share: ₹73.47
  • GF Value™: ₹411.59 vs. price of ₹393.65 (4.4% below fair value)
  • GF Score™: 75/100 with 5 warning signs

No single metric tells the full story. See the BOM:509079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gufic Biosciences Business Description

Other Exchanges GUFICBIO:India
Address SM House, 11 Sahakar Road, 1st to 4th Floor, Vile Parle (East), Mumbai, MH, IND, 400 057
Gufic Biosciences Ltd is engaged in the manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals, and related services. Geographically, it derives a majority of revenue from India. Its product portfolio includes Criticare, Criticare Life, Ferticare, Spark, Herbal, and other products. The company's lyophilized product includes antibiotics, anti-fungal, cardiac, infertility, anti-viral, and a proton-pump inhibitor. It derives maximum revenue from India.
75GF Score

Get the complete analysis for BOM:509079

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹393.65
Price
₹411.59
GF Value